Company / EPS (Basic)
Neurocrine Biosciences EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
$2.56
FY2025
5-year range
$0.40 / $4.38
FY2021-FY2025
Trend
+59.0%
vs FY2024
Sector context
#19 of 208
Health Care
What the data says
Among 208 Health Care companies, Neurocrine Biosciences is in the top 9% for eps (basic). EPS (Basic) has fluctuated over the past 10 years, ranging from $-1.63 in FY2018 to $4.38 in FY2022.
Based on SEC 10-K filings.
2.56 in FY2025 with a 5-year CAGR of +61.9%. Top quartile in the Health Care sector.
Improved from $0.95 to $2.56 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -16.4%
- 5-Year CAGR
- +61.9%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 208This company $2.56 Sector average -$1.02
▼
+351.9% above sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 59.0% year-over-year.
- Ranks #19 out of 208 companies in the Health Care sector.
- Peak eps (basic) was recorded in FY2022.
- Lowest eps (basic) in the period was in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.56 | +59.0% |
| FY2024 | $1.61 | +69.5% |
| FY2023 | $0.95 | -78.3% |
| FY2022 | $4.38 | +995.0% |
| FY2021 | $0.40 | +73.9% |
| FY2020 | $0.23 | +114.2% |
| FY2019 | -$1.62 | +0.6% |
| FY2018 | -$1.63 | -55.2% |
| FY2017 | -$1.05 | -29.6% |
| FY2016 | -$0.81 | -17.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026